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Background: Hepatocellular carcinoma (HCC) is a highly aggressive and heterogeneous disease. HCC cell lines
established from different patients would be useful in elucidating the molecular pathogenesis. However, success of
HCC primary culture establishment remains at low rate. We aim to establish and characterize HCC primary culture
and the derived cell line.
Methods: Fresh tumor tissues were collected from 30 HCC patients. Culture conditions were optimized for the
attachment and growth of the isolated hepatocytes. Granulin-epithelin precursor (GEP), a growth factor reported to
associate with cancer stem cell properties, was examined by flow cytometry to elucidate its role on primary culture
establishment. The primary cell line was characterized in detail.
Results: Cells isolated from 16 out of 30 HCC cases (53%) had viability more than 70% and were subject to
subsequent in vitro culture. 7 out of 16 cases (44%) could give rise to cells that were able to attach and grow in
culture. GEP expression levels significantly correlated with the viability of isolated hepatocytes and success rate of
subsequent primary culture establishment. Cells from HCC patient 21 grew and expanded rapidly in vitro and was
selected to be further characterized. The line, designated HCC21, derived from a Hong Kong Chinese female patient
with HCC at Stage II. The cells exhibited typical epithelial morphology and expressed albumin, AFP and HBV
antigens. The cell line was authenticated by short tandem repeat analysis. Comparative genome hybridization
analysis revealed chromosomal loss at 1p35-p36, 1q44, 2q11.2-q24.3, 2q37, 4q12-q13.3, 4q21.21-q35.2, 8p12-p23,
15q11.2-q14, 15q24-q26, 16p12.1-p13.3, 16q, 17p, 22q and gain at 1q21-q43 in both HCC21 cells and the original
clinical tumor specimen. Sequence analysis revealed p53 gene mutation. Subcutaneous injection of HCC21 cells into
immunodeficient mice showed that the cells were able to form tumors at the primary injection sites and metastatic
tumors in the peritoneal cavity.
Conclusions: The newly established cell line could serve as useful in vitro and in vivo models for studying primary
HCC that possess metastasis ability.
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Hepatocellular carcinoma (HCC) is one of the most
common and aggressive human malignancies worldwide
[1]. It is a highly heterogeneous disease in terms of its
multiple molecular profiles and varied clinical outcomes
[1]. The heterogeneous nature of HCC has impeded pa-
tient prognosis and treatment. Establishment of cell lines
derived from different HCC patients is therefore useful
for comprehensive study of pathogenesis of the disease.
However, cell line establishment from fresh tumor tissues
is technically difficult. Pre-operative procedures such as
embolization and chemotherapy often induce extensive
necrosis in tumor tissues and only small amount of viable
tumor cells are available for subsequent culture. Besides,
contamination and subsequent out-growth of infiltrating
fibroblasts also made the cell line establishment more dif-
ficult. Therefore, the success rate of cell line establishment
from fresh tumor tissues is extremely low [2,3], and the
situation is even worse for cell lines with metastatic poten-
tial [4].
Anoikis is another critical factor hindering cell line es-
tablishment from fresh tissues. Anoikis refers to the
apoptosis in epithelial cells due to the loss of interaction
with their extracellular matrix. During hepatocyte isola-
tion, cells were detached from extracellular matrix. Such
detachment was shown to induce apoptosis of the
freshly isolated cells and greatly decreased the cell viabil-
ity and success rate of subsequent primary culture [5].
Hepatocyte isolation involves the use of collagenase de-
grading collagen and other intercellular material that sup-
port the structure of liver [6], which could trigger anoikis
in freshly isolated hepatocytes [7,8]. Therefore, anoikis re-
sistance is an important property that enables the freshly
isolated cells to survive in the primary culture.
We previously demonstrated the granulin-epithelin
precursor (GEP) was a hepatic oncofetal protein that de-
fined a subpopulation of cancer stem cells (CSCs) in
HCC [9]. It was proposed that CSCs possess certain prop-
erties that allow them to survive better than the other cell
populations during primary culture [10]. However, the
underlying mechanism was not well-understood. It was
previously reported that GEP conferred anchorage-
independence to cancer cells and protected them against
anoikis [11,12]. Therefore, GEP-expressing cells might
have advantage to survive better during hepatocyte isola-
tion through resistance to anoikis.
Cell lines are used extensively in biomedical research as
in vitromodels for the cell type being investigated. Validity
of the data obtained from cell lines depends on their iden-
tities, and how closely they resemble the characteristics of
corresponding original tumor. For cell line identity, it is
revealed that the frequency of cell line misidentification is
high. Recent studies showed that between 18 and 36% of
cell lines were incorrectly designated [13,14]. Accurateidentification of cell lines is crucial during cell line develop-
ment to avoid the risks of using misidentified cells. Short
tandem repeat (STR) profiling has been recommended by
the American Type Culture Collection Standards Develop-
ment Organization (ATCC SDO) Workgroup ASN-0002
as the best method currently available for human cell line
authentication [14,15]. For resemblance with original tu-
mors, cell lines have been criticized for their inherent in-
stability upon long term culture. In addition, culture
process may lead to selective growth of rapidly growing
cells that have more molecular abnormalities. Therefore, it
is suggested that routine cell line authentication back to
the original tissues is needed to ensure that the cell lines
are still representative of the tumors. However, donor tis-
sues are not available for most of the established cell lines,
making such authentication impossible. HCC cell line in
the early passages therefore provides a better experimental
model for studying hepatocarcinogenesis as it resembles
more closely the original tumor.
In present study, we aimed to establish new HCC cell
line from fresh tumor tissues and optimize the culture
conditions to facilitate the cell line establishment. We
attempted to investigate the role of GEP in the viability
of the freshly isolated cells and the success rate of subse-
quent primary culture. Here, we showed that GEP level
was positively correlated with the viability of freshly iso-
lated hepatocytes and the success rate of subsequent pri-
mary culture. The culture conditions for the primary
hepatocytes were optimized and a new cell line, designated
HCC21, was established from the fresh tumor tissue of a
Hong Kong female patient with early staged and moder-
ately differentiated HCC. The line was authenticated, and
its morphology, growth kinetics, migration ability, cytogen-
etic features, and in vivo tumorigenicity were characterized.
This newly established cell line should serve as a useful
model for studying the molecular pathogenesis of HCC.
Results
Primary culture establishment from fresh tumor tissues of
30 HCC patients
Fresh tumor tissues from 30 HCC patients were included
in the primary culture establishment study. After enzym-
atic digestion by type IV collagenase, disaggregated cells
were collected from the tumors. Cell viabilities were
assessed and only cases with cell viability >70% were sub-
ject to subsequent in vitro culture. For cases #1 to #20, 10
out of 20 cases (50%) generated cells with >70% viability.
Primary cells usually require extracellular matrix compo-
nents such as collagen and fibronectin or biodegradable
polymers such as gelatin to promote cell attachment. Of
these, gelatin and collagen were reported to favour sus-
tained viability and functions of hepatocytes [16]. There-
fore, freshly isolated cells were resuspended in AMEM
supplemented with 10% FBS and then seeded onto 6-well
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from 5 out of 10 cases (50%) attached to the culture plates
coated with 0.1% gelatin; while only 2 out of 10 cases
(20%) attached to those coated with 0.1% collagen. Cells
growing on collagen-coated plate were sparse and die
within 1 month, while those growing on gelatin-coated
plate attached better and could establish cell-to-cell con-
tacts (Figure 1A). Therefore, 0.1% gelatin was chosen to
coat plate for primary cell culture of subsequent HCC
cases.
Fibroblast contamination and subsequent out-growth
was frequently found in the process of cell line establish-
ment. Therefore, we started to use defined media, hepato-
cyte culture medium (HCM), for cases #21 to #30. HCM
provides a condition that permits preferential growth of
hepatocytes, while that of contaminating fibroblasts is not
favoured. For cases #21 to #30, 6 out of 10 cases (60%)
generated cells with >70% viability, and the cells were re-
suspended in either AMEM supplemented with 10% FBS
or HCM and then seeded onto 6-well culture plates
coated with gelatin. Among the 6 cases, cells of #21 and
#29 (2 out of 6 cases, 33%) could attach to culture plates
coated with gelatin and grow in both 10% AMEM andFigure 1 Primary culture establishment from fresh tumor tissues of 3
culture from 30 patients was illustrated. Fresh tumor tissues were collected
collagenase to release disaggregated cells. (A) For cases #1-20, cells were r
onto 6-well culture plates coated with either 0.1% gelatin or 0.1% collagen
and #17 were shown. (B) For cases #21-30, cells were resuspended in eithe
6-well culture plates coated with 0.1% gelatin. Phase contrast microscopy iHCM (Figure 1B). Fibroblast out-growth was observed in
both cases cultured in AMEM with 10% FBS, while fibro-
blasts gradually decreased and disappeared in those cul-
tured in HCM. Cells from #21 grew well and could
propagate in subsequent passages, while those from #29
died gradually after one passage. Extensive characterization
of cells from #21 was then performed.Correlation of GEP expression with success rate of HCC
primary culture
We previously demonstrated that GEP was a hepatic
oncofetal protein that defined CSC population in HCC
[9]. CSCs are proposed to possess certain properties that
allow them to survive better in primary culture [10].
Further analysis with clinico-pathological features re-
vealed that increased GEP level was significantly associ-
ated with poor differentiation (p = 0.044) (Additional file
1: Table S1). As tumors with poor differentiation were
more aggressive and associated with more stem-cell fea-
tures [17], the result implied that GEP might contribute
to the aggressiveness and stemness of HCC, and GEP-
expressing cells might survive better in primary culture.0 HCC patients. Experimental protocol for establishing primary HCC
from HCC patients and underwent enzymatic digestion by type IV
esuspended in AMEM supplemented with 10% FBS and then seeded
. Phase contrast microscopy images of cultured cells from cases #14
r AMEM supplemented with 10% FBS or HCM and then seeded onto
mages of cultured cells from cases #21 and #29 were shown.
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flow cytometry, and studied their relationship with the cell
viability and success rate of cell line establishment. GEP
level was shown to be significantly correlated with the via-
bility of cells isolated from the fresh tumor tissues (n = 28,
Spearman’s ρ correlation coefficient = 0.729, p =0.000)
(Figure 2A). Cells isolated from 7 cases showed viabil-
ity >70% and could successfully grow in culture, and
their GEP levels were significantly higher than those
that failed to grow or the viability was <70% (p = 0.001,
Figure 2B). The results suggested that GEP might be
an important factor for facilitating cell line establish-
ment from fresh HCC tumor tissues.
During hepatocyte isolation, cells were detached from
extracellular matrix. Such detachment induced anoikis
and greatly decreases the cell viability and success rate
of subsequent primary culture [5]. GEP was shown to
protect cancer cells against anoikis [11,12], and might
therefore facilitate primary culture establishment by con-
ferring anoikis resistance to the HCC cells. To support
this hypothesis, Hep3B cells were sorted based on GEP
expression. Post-sorting analysis was performed andFigure 2 Correlation of GEP expression with success rate of HCC prim
the cells freshly isolated from HCC tissues (n = 28, Spearman’s ρ correlation
cytometry and expressed as mean fluorescence intensity (MFI) after subtrac
levels (MFI) of the cells with viability > 70% and could grew on culture plat
failed or viability <70% (not viable or no growth) (n = 28, p = 0.001). (C) He
Unsorted control cells, sorted GEPhigh and GEPlow cells were then cultured
12 h. Cells were harvested and stained for annexin V-propidium iodide for
were defined as viable cells, which were quantified by flow cytometric ana
sorted GEPhigh cells.purity was shown to be >80% (Additional file 1: Figure S1).
Unsorted control cells, sorted GEPhigh and GEPlow cells
were then cultured in attachment free environment for
12 h. Viability of GEPlow cells was significantly lower than
unsorted and sorted GEPhigh cells (p = 0.025 and p = 0.011,
respectively), suggesting that GEP was crucial for protect-
ing HCC cells from anoikis-induced apoptosis (Figure 2C)
and might facilitate primary culture establishment.
Phenotypic characterization of HCC21 cells
The cells derived from HCC case #21, designated HCC21,
reached 80% confluency at 10 days after initial culture, and
sub-passage was performed successfully without significant
cell death. The cells began to grow quickly at the 6th pas-
sage and were passaged for more than 50 generations
thereafter. Flow cytometric analysis showed that albumin +
cells of the original tumor #21 were 83.2%. Upon cultu
re for about 10 days in hepatocyte culture medium, albu-
min + cells increased to 88.9%, which was further enriched
to more than 98% after 6 passages (Figure 3A), confirming
that HCC21 cells were hepatocytes. HCC21 cells grew as
adherent monolayer with epithelial morphology (Figure 3B)ary culture. (A) GEP levels significantly correlated with the viability of
coefficient = 0.729, p = 0.000). GEP level was measured by flow
ting the non-specific background signal (isotype control). (B) GEP
e successfully (viable and growth) were significantly higher than those
p3B cells were sorted for surface GEP expression by magnetic sorting.
in 10% FBS-supplemented AMEM in ultra-low attachment plate for
apoptosis. Cells negative for both annexin V and propidium iodide
lysis. Viability of GEPlow cells was significantly lower than unsorted and
Figure 3 Phenotypic characterization of HCC21 cells. (A) Albumin levels of freshly isolated cells from patient’s tumor specimen, HCC21 cells
at passage 1 and 6 were measured by flow cytometry. Percentages of albumin + cells were indicated in the histograms. (B) Phase-contrast microscopy
images of cultured HCC21 cells at passages 6 and 30. (C) Growth curve of HCC21 cells at passage 10. (D) Wound healing assay showing the migration
ability of HCC21 cells at passage 10.
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sages. Growth curve of HCC21 cells is shown in Figure 3C.
The population doubling time of HCC21 was approxi-
mately 95 h. Wound healing assay was performed to assess
the migration ability of HCC21 cells. The cells started to
migrate a day after the wound was made, and the wound
healing was completed after 3 days (Figure 3D). The migra-
tion ability of HCC21 cells echoed the histology observa-
tion that venous infiltration (micrometastasis) was observed
in the surgical specimen.STR profile analysis of HCC21 cells
The DNA samples of HCC21 early and late passages (11
and 50, respectively), original tumor and adjacent non-
tumor liver tissue were subjected to DNA fingerprinting
analysis. A total of 15 STR loci (CSF1P0, D2S1338,
D3S1358, D5S818, D7S820, D8S1179, D13S317, D16S539,
D18S51, D19S433, D21S11, FGA, TH01, TPOX, vWA)
were co-amplified in each sample. AMLEO locus at the sex
chromosomes was also examined. The data were analyzed
and allele(s) of each locus were determined (Table 1). The
STR profiles of HCC21 cells and the original tumor were
identical, suggesting that they came from the same person.
Besides, loss of heterozygosity (LOH) was observed in 2loci, D16S539 and FGA in original tumor, and the aberra-
tions were retained in HCC21 cells (Figure 4).
Array-based comparative genomic hybridization (aCGH)
analysis
Changes in genomic copy number in HCC21 cells and ori-
ginal tumor were characterized by aCGH analysis. aCGH
arrays were performed using DNA from original tumor
and that from the HCC21 cells 6 months after its estab-
lishment. Chromosomal aberrations including chromo-
somal loss at 1p35-p36, 1q44, 2q11.2-q24.3, 2q37, 4q12-q
13.3, 4q21.21-q35.2, 8p12-p23, 15q11.2-q14, 15q24-q26,
16p12.1-p13.3, 16q, 17p, 22q and gain at 1q21-q43 were
observed in both the original tumor specimen and HCC21
cells (Figure 5). Noted the STR profiles showed LOH at
FGA (at chromosome 4q28) and D16S539 (at chromo-
some 16q24.1), and that corroborated the aCGH data with
chromosomal loss at 4q21.21-q35.2 and 16q in both the
original clinical tumor specimen and the derived HCC21
cells.
TP53 mutational analysis
p53 has been reported to be frequently mutated and
overexpressed in HCCs [18]. Result from western blot
showed that p53 protein was present in HCC21 cells.
Table 1 STR profiles of HCC21 cells at passage 11 and 50, adjacent non-tumor liver tissue and tumor specimen from
patient
HCC21 HCC21 HCC21 HCC21
Cells (passage 11) Cells (passage 50) Adjacent liver tissue Tumor specimen
D8S1179 14 14 14 14
D21S11 30, 31.2 30, 31.2 30, 31.2 30, 31.2
D7S820 10, 11 10, 11 10, 11 10, 11
CSF1PO 11 11 11 11
D3S1358 15, 17 15, 17 15, 17 15, 17
TH01 9 9 9 9
D13S317 10 10 10 10
D16S539 9 9 9, 11 9, 11 (LOH)
D2S1338 19 19 19 19
D19S433 13.2, 14.2 13.2, 14.2 13.2, 14.2 13.2, 14.2
vWA 16, 17 16, 17 16, 17 16, 17
TPOX 8, 12 8, 12 8, 12 8, 12
D18S51 12, 15 12, 15 12, 15 12, 15
Amelogenin X X X X
D5S818 10, 11 10, 11 10, 11 10, 11
FGA 24 24 24, 25 24, 25 (LOH)
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included as wild-type and mutant controls, respectively
(Figure 6A). Subsequent analysis by DNA sequencing indi-
cated a point mutation (Gly → Arg) (GGA → AGA) at
codon 266 of exon 8 in both the HCC21 cells and tumor
specimen (Figure 6B). PLC/PRF/5 was included as p53 mu-
tant control (codon 249 of exon 7) and no mutation was
found in exon 7 of HCC21 cells (data not shown).
Tumorigenicity and metastatic potential in
immunodeficient mice
HCC21 cells were injected subcutaneously into 4 nude
and 3 NOD/SCID mice. About 2 months after injection,
visible tumors developed in all mice at the site of inocu-
lation (Figure 7A), indicating that HCC21 cells were
tumorigenic. We assessed the expression of HCC markers
including AFP and HBV antigen [19] in the HCC21 cells
and xenograft tumors. Western blot analysis showed that
HCC21 cells and xenograft tumors in both nude and
NOD/SCID mice retained the expression of HBV core
antigen and AFP, which was consistent with original
resected tumor (Figure 7B). Most importantly, secondary
tumors were found in the peritoneal cavities of 2 NOD/
SCID mice (Figure 8A). Histological sections of the xeno-
grafts showed neoplastic hepatocytes proliferation in
broad trabeculae and acinar pattern, morphologically con-
sistent with HCC. In addition, the metastatic (secondary)
lesions were morphologically similar to the primary tu-
mors (Figure 8B, upper panel). Besides, we have examined
the expression of AFP in the primary and secondaryxenograft tumors, in comparison to the patient’s tumor
and adjacent non-tumor liver tissue specimen by immu-
nohistochemical staining. Results showed that AFP pro-
tein was expressed at high levels in the tumor specimen,
and also in the primary and secondary xenograft tumors.
AFP protein could also be detected in adjacent non-tumor
liver tissue specimen, but the signal was lower than the
tumor counterpart (Figure 8B, middle panels). This fur-
ther demonstrated that the tumor characteristics had been
preserved from the original tumor specimen to the pri-
mary and metastasized tumor xenografts.
The aCGH analysis revealed loss of 16q in HCC21
cells, which region contained E-cadherin gene (at chromo-
some 16q22.1). E-cadherin is an adhesion molecule crucial
for inhibiting metastasis by connecting homophilic cells
[20-22]. Loss of E-cadherin was reported to associate with
high incidence of lymph node metastasis in various can-
cers, including HCC [23-25]. Therefore, we examined the
expression of E-cadherin in HCC21 cells by western blot.
HepG2, HCC cell line without metastatic potential, was
included as positive control for the presence of E-
cadherin. Result showed that E-cadherin protein was ab-
sent in HCC21 cells (Figure 8C), thereby providing further
evidence for the metastatic potential of the cells.
Discussion
HCC is a highly heterogeneous in terms of molecular
profiles and clinical outcomes [1]. Establishment of pri-
mary HCC culture derived from different patients is
therefore useful for comprehensive study of the etiology
Figure 4 DNA fingerprinting of HCC21 cells. Comparison of genotyping results in adjacent non-tumor liver tissue and tumor specimen from
patient, and HCC21 cells at passage 11 and 50. Patient’s tumor specimen and cultured HCC21 cells demonstrated loss of heterozygosity in (A)
D16S539 and (B) FGA when compared to adjacent non-tumor liver tissue.
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lishment of human cell lines from fresh patients’ tumors
is technically difficult, partly due to the low viability of
the freshly isolated HCC cells. Here, we showed for the
first time that GEP protein levels of HCC cells were sig-
nificantly correlated to the cell viability and also the suc-
cess rate of subsequent primary culture. GEP-expressing
cells were able to survive better during hepatocyte isola-
tion, which was potentially due to their resistance to anoi-
kis. The findings therefore suggested that GEP might be
an important factor for facilitating cell line establishment
from fresh HCC tumor tissues.
Recent reports on GEP binding partners might provide
some hints on the underlying mechanism for GEP-
mediated anoikis resistance. GEP was demonstrated as a
ligand of tumor necrosis factor receptors (TNFRs) in hu-
man chondrocytes and disturbed TNFα signaling [26].
Notably, TNFR1 has been shown to be crucial on anoikis
execution in cancer progression [27]. In addition, our
group have recently demonstrated that GEP interacted
with heparan sulfate on HCC cell surface [28]. Heparansulfate was essential for anoikis resistance and survival in
mouse dermal fibroblasts [29] and in rat embryo fibro-
blasts [30]. We have further shown that tropomyosin 3
was the intracellular binding partner of GEP in liver can-
cer cells [31]. Independently, tropomyosin-1 was reported
to regulate anoikis in breast cancer cells [32]. Therefore,
further investigations are warranted to investigate the
roles of TNFR, heparan sulfate and tropomyosins on
GEP-mediated anoikis resistance in human cancer cells.
Cell line authentication is crucial during cell line de-
velopment to avoid the risks of using misidentified cells.
Recent studies have shown that more than 360 cell lines
were cross-contaminated or misidentified without au-
thenticated stock, and the validity of the studies using
these cell lines was in doubt [33]. A cell line is consid-
ered misidentified when its DNA profile is not consist-
ent with the individual from whom it was derived from.
Here, we showed that the STR profiles of HCC21 cells
and original resected tumor were identical, confirming
that HCC21 cells and the tumor came from the same
person.
Figure 5 CGH analysis of HCC21 cells and the original tumor. Vertical profiles of chromosomes 1, 2, 4, 8, 15, 16, 17 and 22 are shown with a
log2 ratio, which represents the difference between tumor and normal DNA copy number. Ratio of 0 indicates that there is no change in copy
number between tumor and normal cell DNA. Positive and negative log2 ratios indicate the gain and loss of tumor DNA copy number,
respectively. The left panel of each plot represents the chromosome of the original clinical tumor specimen, while the right panel represents that
of HCC21 cells at passage 10.
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this has impeded the elucidation of molecular mechanisms
underlying hepatocarcinogenesis. Chromosomal aberra-
tions in HCC21 cells were examined using CGH. The re-
sults showed that chromosomal aberrations were observed
in both the primary tumor and HCC21 derived cells in-
cluding loss at 1p35-p36, 1q44, 2q11.2-q24.3, 2q37, 4q12-
q13.3, 4q21.21-q35.2, 8p12-p23, 15q11.2-q14, 15q24-q26,
16p12.1-p13.3, 16q, 17p, 22q and gain at 1q21-q43. Of
these, gain at 1q was previously reported to be associated
with HCC development [35-37]. Loss of 4q11-23 was pre-
viously reported to be observed in tumor larger than 3 cm.This is consistent with the tumor size of patient (8.5 cm).
Chromosome 4q abnormality was significantly associated
with HCC [38,39]. LOH at 4q was reported to strongly cor-
relate with AFP elevation in HCC [40], and this echoes the
high serum AFP level (30690 ng/ml) in the patient. Loss of
17p was frequently found in HCC, which was generally ex-
plained by loss of the TP53 gene [41-43]. Loss of 8p was
observed in both HCC21 cells and original tumor. This ab-
erration was previously reported to significantly correlate
with tumor metastasis in HCC.
Mutations in the TP53 tumor suppressor gene are
found in approximately 50% of human cancers and the
Figure 6 TP53 mutational analysis in HCC21 cells. (A) Expression of p53 protein in HCC21 cells, HepG2 (wild-type p53) and PLC (p53
mutation at codon 249). (B) Sequencing analysis of TP53 gene revealed a point mutation (Gly→Arg) in codon 266 of exon 8 in HCC21 cells
(passage 11) and patient’s tumor specimen, but not PLC.
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ing to amino acid substitutions [43-45]. Since point mu-
tation of genes can occur during serial in vitro passage,
gene analysis of primary tumors is therefore indispens-
able. We showed here that a point mutation in the p53
suppressor gene (Gly → Arg at codon 266 at exon 8)A
Figure 7 Tumorigenicity of HCC21 cells in immunocompromised mice
2x106 and 1x106 HCC21 cells, respectively, after 12 weeks. The middle pane
after injection (scale bar = 10 mm). The lower panel shows the tumorgenic
in patient’s tumor specimen, HCC21 xenograft tumors in NOD/SCID and nuwas present in both HCC21 cells and the original tumor,
thereby confirming the mutation was not induced during
serial in vitro passage. This mutation has not been re-
ported in HCC. Similar to other p53 mutation, this mu-
tation may also result in biological altered protein with
increased stability and nuclear accumulation in the cellsB
. (A) Nude mice and NOD/SCID mice injected subcutaneously with
l shows the subcutaneous tumors derived from HCC21 cells 12 weeks
ity of HCC21 cells. (B) Protein expression of HBV core antigen and AFP
de mice, and cultured HCC21 cells at passage 12.
Figure 8 Metastatic potential of HCC21 cells in NOD/SCID mice. (A) Subcutaneous injection of HCC21 cells into NOD/SCID mice led to
primary tumor development at the site of injection and secondary tumors in the peritoneal cavity (scale bar = 10 mm). (B) Histological analysis of
patient’s tumor and adjacent non-tumor liver tissues, primary and secondary xenograft tumors established in NOD/SCID mice. Sections were
stained with haematoxylin and eosin (H&E) (upper panel), AFP (middle panel) and rabbit Ig control (lower panel). (C) Undetectable protein expres-
sion of E-cadherin in HCC21 (passage 12) while HepG2 served as positive control.
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level of p53 in HCC21 cells, when compared with that
in HepG2, the p53 wild type control cell line. However,
further investigation is needed to elucidate the detailed
mechanism.
HCC has been reported with high incidence of metastasis
[46]. The underlying mechanism of metastasis is still poorly
elucidated, which is probably due to the lack of good meta-
static HCC cell line models for the related studies. Al-
though a number of human HCC cell lines are currently
available, few have demonstrated prominent metastatic
potential [47,48]. To date, MHCC97 is the only well-
characterized HCC cell line with metastatic potential [47].
However, it was established from subcutaneous xenograftof a metastatic model of human HCC in nude mice by
means of alternating cell culture in vitro and growth in
nude mice. Xenografts generated by implantation of cell
lines were shown to have poor predictive power for transla-
tion of preclinical efficacy into clinical outcome [49].
HCC21, on the other hand, derived from fresh tumor tissue
of HCC patient, might therefore serve as a better model for
studying the molecular mechanism of metastasis in HCC.
Epithelial-mesenchymal transition (EMT) plays an im-
portant role in cancer progression and metastasis [50,51].
A hallmark of EMT is down-regulation of E-cadherin, a
cell adhesion molecule essential for the establishment of
stable adherent junctions. It has been reported that re-
pression of E-cadherin is associated with dedifferentiation,
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tastasis in several cancers, including HCC [23-25]. Here,
CGH analysis showed that HCC21 cells exhibited loss of
16q21-24, which contained E-cadherin gene. E-cadherin
protein was also confirmed to be absent in HCC21 cells,
suggesting that the metastatic potential of the cells was at
least partially due to the loss of E-cadherin. In addition,
MMPs are also crucial for tumor metastasis by degrading
and remodeling the extracellular matrix. A number of
ECM degrading MMPs, such as MMP1, MMP2 and
MMP14, have been implicated in the process of tumor in-
vasion and metastasis [52]. Further investigation is needed
to elucidate the role of these MMPs in the metastatic po-
tential of HCC21 cells.
Most of the currently available cancer cell lines are de-
rived from late-staged and poorly-differentiated tumors
such that the cells have accumulated the mutations re-
quired for indefinite growth in vitro. However, cell lines
from early-staged and well-differentiated tumors are
needed for better understanding of the HCC progression
and pathogenesis. The doubling time of HCC21 is
95 hours, which is relatively long when compared with
other established HCC cell lines. The original tumor was
classified as stage II based on TNM system and graded
as moderately differentiated. Therefore, this cell line will
serve as a relatively early-staged and moderately differ-
entiated HCC model for biomedical research on early
stage of hepatocarcinogenesis.
Conclusions
In present study, a novel HCC cell line from a Hong Kong
female patient with early-staged and moderately differenti-
ated HCC was established and authenticated. This cell line
reproduces the characteristics of the original tumor, and
could provide researchers with a well-delineated and
early-passage cell line model to investigate the biology and
molecular details of HCC. Authentication of cell line is
important to ensure that the cell line is representative of
the original tumor, and serves as a relevant tool for re-
search studies. In addition, we optimized the protocol for
primary culture of HCC. The study also showed that GEP
might be an important factor determining the viability of
the freshly isolated HCC cells and therefore affect the suc-
cess rate of subsequent primary culture. The study pro-
vided an improved protocol for establishment of primary
culture of HCC, detailed characterization and authentica-
tion on the newly established cell line.
Methods
Specimen collection
The study protocol was approved by the Institutional
Review Board of the University of Hong Kong / Hospital
Authority Hong Kong West Cluster (HKU/HA HKW
IRB). Between July 2010 and March 2011, 30 patientshaving curative partial hepatectomy or liver transplant-
ation for HCC at Queen Mary Hospital, Hong Kong,
were recruited after written informed consent was ob-
tained. Tumors and non-tumorous tissues were collected
from the resected specimens. A portion of tumor tissues
was freshly processed for cell culture and flow analysis,
while DNA and proteins were extracted from the snap
frozen tissues.
Original tumor tissue from which HCC21 cells was de-
rived was obtained from a 42-year-old Hong Kong Chinese
female patient who underwent curative partial hepatec-
tomy. Tumor size was 8.5 cm in diameter. The patient
was seropositive for hepatitis B virus (HBV), and serum
α-fetoprotein (AFP) level was 30690 ng/mL (reference
range <10 ng/mL). A diagnosis of HCC arising in a cir-
rhotic liver was confirmed by histological examination.
Venous infiltration was observed, indicating the aggressive-
ness of the tumor. The tumor was classified as stage II
according to the pathological tumor-node-metastasis (pT
NM) staging system 2009 version, and graded as moder-
ately differentiated.
Primary culture and cell line establishment
Fresh tumor tissues were rinsed with AMEM medium
(Invitrogen, Carlsbad, CA) supplemented with 50 units/
ml Penicillin G (Invitrogen) and 50 μg/ml streptomycin
(Invitrogen), and then minced into 1-mm3 pieces. After
digestion with type IV collagenase (Sigma, St. Louis,
MO) for 5 min at 37°C for 3 times, disaggregated cell
suspension was obtained by filtering through a 40 μm
cell strainer (BD Biosciences, San Jose, CA). After lysis
of red blood cells by ACK lysis buffer (Invitrogen), cells
were washed with AMEM medium. The cells were then
resuspended in either AMEM supplemented with 10%
FBS (Invitrogen) or hepatocyte culture medium (Lonza,
Basel, Switzerland), and then seeded onto 6-well culture
plates coated with either 0.1% gelatin (Sigma) or 0.1%
type I collagen (Sigma). Cells were incubated at 37°C in
a humidified atmosphere at 95% air and 5% CO2 and left
untouched for 2 days. The culture medium was then
changed twice a week and cells were sub-passaged when
they reached 70-80% confluency.
For HCC21 cells, a split ratio of 1:1 was applied in the
early passages (passage 1 to 5), thereafter increased to
1:3. Cells were collected at different passages and put in
freezing medium containing 50% hepatocyte culture
medium, 40% FBS and 10% DMSO, and stored in liquid
nitrogen. The cells were tested for mycoplasma contam-
ination and the result was negative.
Anoikis assay
Hep3B cells were sorted for GEPhigh and GEPlow sub-
populations by magnetic activated cell sorting (Miltenyi
Biotec) as previously described [9]. After cell isolation,
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assess cell viability and purity by trypan blue staining
and flow cytometry, respectively. Post-sorting analysis
typically indicated purities of at least >80% with minimal
cell death (<10%). Unsorted control cells, sorted GEPhigh
and GEPlow cells were then cultured in 10% FBS-
supplemented AMEM in ultra-low attachment plate
(Corning Inc, Corning, NY) for 12 h. Cells were harvested
and stained for annexin V-propidium iodide (BD Biosci-
ences) for viability, in which cells negative for both annexin
V and propidium iodide were defined as viable cells. Viable
cells were quantified by flow cytometric analysis.
Immunofluorescence staining and flow cytometric
analysis
Cells were permeabilized with ice-cold 0.1% saponin and
then incubated with FITC-conjugated mouse anti-human
GEP antibody (described previously [53]) (Versitech Ltd,
Hong Kong), mouse anti-human albumin (R&D systems,
Minneapolis, MN) or equal amount of mouse IgG isotype
(Sigma). Cells were washed with 0.1% saponin and then
subject to flow cytometric analysis. Results were expressed
as percentage of positive cells or mean fluorescence inten-
sity (MFI), after subtracting the non-specific background
signal (isotype control).
Morphological examination and growth kinetics
Cells were routinely monitored and photographed with a
phase-contrast microscope. Cells of passages 6 and 16
were studied to measured the population doubling time,
which was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay for 5 con-
secutive days.
Would healing assay
Cells were seeded onto a 6-well culture plate and incu-
bated for 24 hr. A wound was made by scraping a 20 μl
pipette tip across the cell monolayer. Cells were rinsed
with PBS and cultured in HCM for 3 days. Cell move-
ment toward the wound was observed under a phase-
contrast microscope every 24 h after the wound was
made.
Short tandem repeat (STR) analysis
DNA samples of the HCC21 cells at passage 11 and 50,
original tumor and the adjacent non-tumor liver tissue
from the patient were subjected to DNA fingerprinting
analysis using the AmpF/STR Identifiler Plus PCR Ampli-
fication Kit (Invitrogen). A total of 15 STR loci (CSF1P0,
D2S1338, D3S1358, D5S818, D7S820, D8S1179, D13S317,
D16S539, D18S51, D19S433, D21S11, FGA, TH01, TPOX,
vWA) were co-amplified in each sample and detected on
an ABI 3130 Genetic Analyzer. AMLEO locus at the sex
chromosomes was also examined. The data were analyzedand allele(s) of each locus were determined by GeneScan
and GeneMapperTM ID Software (Invitrogen).
Array-based comparative genomic hybridization (aCGH)
Genomic DNA was extracted from HCC21 cells and the
original tumor. The Agilent human 44 K CGH micro-
array (Agilent Technologies, Santa Clara, CA) with an
average probe spatial resolution of ∼ 35 kb was utilized.
Genomic DNA at 1 μg was labelled by the Agilent Gen-
omic DNA Labeling Kit PLUS (Agilent Technologies).
The hybridized array was scanned by an Agilent Micro-
array Scanner and data were analysed by Agilent Feature
Extraction 9.1 followed by computation and normalization
using CGH Analytics v3.4. Putative chromosome copy
number loss was defined by intervals of two or more adja-
cent probes with log2 ratios suggestive of a deletion when
compared with the log2 ratios of adjoining probes. The
Quality-Weighted Interval Score algorithm (ADM2) with
a value of 6.0 was used to compute and assist the identifi-
cation of aberrations for a given sample.
Western blot analysis
Total protein was extracted with cell lysis buffer (Cell
Signaling Technology, Boston, MA) in the presence of
complete protease inhibitor cocktail (Roche, Mannheim,
Germany) and separated in 8-10% SDS PAGE gel. Pro-
teins were then electro-transferred onto polyvinylidene
difluoride membranes, subsequently incubated with pri-
mary anti-human antibodies, detection by horseradish
peroxidase-labeled secondary antibodies, and visualized
with Enhanced Chemiluminescence Western Blotting
Detection Kit (Amersham Biosciencse, Piscataway, NJ).
TP53 mutational analysis
Direct DNA sequencing was performed for exons 4-9 of
p53, in which >80% of all mutations were observed
[54,55]. Primer sets and reaction conditions were adopted
from Lehman et al [56]. DNA was amplified by polymerase
chain reaction and direct DNA sequencing was performed
with the BigDye Sequencing kit (Invitrogen). Electrophor-
esis and sequence analysis were performed using the ABI
PRISM 3100 (Invitrogen).
In vivo tumorigenicity in immunodeficient mice
The study protocol was approved by and performed in
accordance with the Committee of the Use of Live Ani-
mals in Teaching and Research at the University of Hong
Kong. Cells from passage 8 were harvested, washed, and
resuspended in hepatocyte culture medium (HCM). 1x106
cells were injected subcutaneously into the right flank of
each athymic nude or NOD/SCID mouse (4 weeks old).
The mice were examined every week for the development
of tumors and tumor-bearing mice were sacrificed when
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Immunohistochemical staining
Immunohistochemistry was performed with the Dako
Envision Plus System (Dako, Carpinteria, CA) following
the manufacturer’s instruction with modifications. Briefly,
antigen retrieval was performed by microwave with sec-
tions immersed in citrate buffer. Followed by endogenous
peroxidase blocking, tissues were stained with rabbit anti-
human AFP antibody (Dako) or rabbit Ig (R&D Systems,
Minneapolis, MN). The signal was detected by horseradish
peroxidase-conjugated secondary antibody and color was
developed with diaminobenzidine as the chromogen. The
tissue sections were then counterstained with hematoxylin.
Statistical analyzes
All data were expressed as mean values + standard devi-
ation (SD) from at least three independent experiments.
Differences between groups were assessed by the Student’s
t test. A probability (p) < 0.05 was considered significantly
different. All analyzes were performed using the statistical
software GraphPad Prism for Windows, Version 3.00
(GraphPad Software, CA).
Additional file
Additional file 1: Figure S1. Post-sorting analysis on GEP expression in
unsorted Hep3B and freshly isolated GEPhigh, and GEPlow subpopulations.
Table S1. Clinicopathological features of HCC in relation to GEP
expression.
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